跳至主要内容
临床试验/NCT05527535
NCT05527535Unknown不适用

Expansion of Integrated AI Solution for Diabetic Retinopathy Screening in Thailand: An Implementation Research

Rajavithi Hospital0 个研究点目标入组 34,500 人开始时间: 2022年10月3日最近更新:
适应症

试验速览

阶段
不适用
入组人数
34,500
主要终点
Effectiveness of AI in diabetic retinopathy screening

研究概览

简要总结

Efficiency and effectiveness of real-world diabetic retinopathy screening by artificial intelligent (AI) are limited. Investigators will implement AI for diabetic retinopathy screening in 13 health districts in Thailand and investigate the efficiency, effectiveness as well as patients and health care personnel's satisfaction by an implementation research.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 1 or 2 diabetes mellitus patients whose name are in primary hospital record
  • No full-time ophthalmologists in those primary hospital
  • Age more than or equal to 18 years
  • Eligible for fundus photo imaging at least 1 eye

排除标准

  • Type 1 or 2 diabetes mellitus patients whose name are in primary hospital record that have full-time ophthalmologists
  • Patients who previously diagnosed with other causes of macular edema, for example, Age-related Macular Degeneration, Radiation Retinopathy, Retinal Vein Occlusion etc.
  • History of retinal laser or surgery
  • Other ocular diseases that require referral to ophthalmologists
  • Not eligible for fundus photo imaging for both eyes (any causes)

结局指标

主要结局

Effectiveness of AI in diabetic retinopathy screening

时间窗: Throughout the whole period of screening, approximately 6 months

Referral adherance of patients in AI group in percentage

Efficiency of AI in diabetic retinopathy screening

时间窗: Throughout the whole period of screening, approximately 6 months

Cost in development and implement of AI system in Thai baht unit

次要结局

  • Satisfaction of patients and health care personnel in AI-based screening(At the end of the screening, approximately at Month 6)

研究者

申办方类型
Other Gov
责任方
Sponsor

相似试验